Tier 3 — preclinical

Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies

Zeyi Lv, Zhuo Pan, Yue Huang, Hao Yang, Xinrong Li
Frontiers in pharmacology 2025 16:1673712

Bibliography

PubMed
PMID 41357894
PubMed Central
PMC12676024
DOI
10.3389/fphar.2025.1673712
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Study snapshot

DesignSystematic review and meta-analysis of animal allergy models
ModelPreclinical evidence synthesis
Sample13 rodent studies
InterventionQuercetin across allergic-disease models
DurationExperiment-specific schedules
EndpointsInflammatory measures

What the study showed, in plain terms

Published in 2025, this source examined allergies, histamine and mast cells. Design: Systematic review and meta-analysis of animal allergy models. Sample/model: 13 rodent studies. The exposure or intervention was Quercetin across allergic-disease models. Follow-up or treatment period: Experiment-specific schedules.

Selected IgE, histamine, cytokine, and immune-cell measures improved in pooled animal results.

Large heterogeneity and methodological limitations constrain translation. This is not human evidence for treating mast-cell activation syndrome, asthma, or anaphylaxis.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Allergies: Hay Fever Evidence and Limits. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Selected IgE, histamine, cytokine, and immune-cell measures improved in pooled animal results.
  • The recorded outcome domains were Inflammatory measures.
  • The result applies to the tested exposure: Quercetin across allergic-disease models; Experiment-specific schedules.

What this study can and cannot tell us

  • Large heterogeneity and methodological limitations constrain translation. This is not human evidence for treating mast-cell activation syndrome, asthma, or anaphylaxis.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology